Plasma homocysteine levels & 677C→T methylenetetrahydrofolate reductase gene polymorphism in patiensts with coronary artery disease of different severity

Indian Journal of Medical Research

Volumn 127, Issue 2, 2008, Pages 154-158

  Rassoul, F ^a   Richter, V ^a   Hentschel, B ^b   Geisel, J ^c   Herrmann, W ^c   Kuntze, T ^b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Coronary artery disease; GENSINI score; Homocysteine; Methylenetetrahydrofolate reductase polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOSINE; HOMOCYSTEINE; THYMINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; PATHOGENESIS; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEMOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 46649094604     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Ueland PM. Plasma total homocysteine and hospitalization for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med 2002; 166: 1374-81.
2. Graham IM, Daly LE, Refsum H, Robinson K, Brattstrom LE, Ueland MP, et al Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997; 277: 1775-81.
3. Lievers KJ, Boers GH, Verhoef P, den Heijer M, Kluijtmans LA, van der Put NM, et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med 2001; 79: 522-8.
4. Guo H, Lee JD, Ueda T, Shan J, Wang J. Plasma homocysteine levels in patients with early coronary artery stenosis and high risk factors. Jpn Heart J 2003; 44: 865-71.
5. Cattaneo M. Hyperhomocysteinemia and atherothrombosis. Ann Med 2000; 32 (Suppl 1): 46-52.
6. Rassoul F, Richter V, Janke C, Purschwitz K, Klötzer B, Geisel J, et al. Plasmahomocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology 2000; 51: 189-96.
7. Kark JD, Sinnreich R, Rosenberg IH, Jacques PF, Selhub J. Plasma homocysteine and parenteral myocardial infarction in young adults in Jerusalem. Circulation 2000; 105: 2725-9.
8. Harmon DL, Doyle RM, Meleady R, Dolye M, Shields DC, Barry R, et al. Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 1999; 19: 208-11.
9. Kluijtmans LA, Whitehead AS. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease: evidence that all three MTHFR C677T genotypes confer different levels of risk. Eur Heart J 2001; 22: 294-9.
10. Geisel J, Jodden V, Obeid R, Knapp JP, Bodis M, Herrmann W. Stimulatory effect of homocysteine on interleukin-8 expression in human endothelial cells. Clin Chem Lab Med 2003; 41: 1045-8.
11. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: Implications for vascular disease. Circulation 2001; 103: 2717-23.
12. Silverman MD, Tumuluri RJ, Davis M, Lopez G, Rosenbaum JT, Lelkes PI. Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol 2002; 22: 587-92.
13. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli RF, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-600.
14. Herrmann W, Schorr H, Purschwitz K, Rassoul F, Richter V. Total homocysteine, vitamin B12 and total antioxidant status in vegetarians. Clin Chem 2001; 47: 1094-101.
15. Kang SS, Wong PW, Zhou J. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988; 37: 611-3.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthew RG, et al. A candidate genetic risk factors for vascular disease: A common mutation in methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification. Nat Genet 1995; 10: 110-3.
17. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arteriosler Thromb Vasc Biol 1997; 17: 569-73.
18. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
19. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52.
20. Kolling K, Ndrepepa G, Koch W, Braun S, Mehilli J, Schomig A, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol 2004; 93: 1201-6.
21. Tsai WC, Li YH, Tsai LM, Chao TH, Lin LJ, Chen TY, et al. Correlation of homocysteine levels with the extent of coronary atherosclerosis in patients with low cardiovascular risk profiles. Am J Cardiol 2000; 85: 49-52.
22. Montalescot G, Ankri A, Chadefaux-Vkemans B, Blacher J, Philippe F, Drobinski G, et al. Plasma homocysteine and the extent of atherosclerosis in patient with coronary artery disease. Int J Cardiol 1997; 60: 295-300.
23. Yoo HJ, Park JE, Hong KP, Lee SH, Kim DK, Lee WR, et al. Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans. Thromb Res 1999; 94: 45-52.
24. Bozkurt A, Toyaksi H, Acartürk E, Tuli A, Cayli M. The Effects of hyperhomocysteinemia on the presence, extent, and severity of coronary artery disease. Jpn Heart J 2003; 44: 357-68.
25. Bozkurt E, Keles S, Acikel M, Islek M, Atesal S. Plasma homocysteine levels and the angiographic extent of coronary artery disease. Angiology 2004; 55: 265-70.
26. Bokhari SW, Bokhari ZW, Zell JA, Lee DW, Faxon DP. Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients. Coron Artery Dis 2005; 16: 153-61.
27. Gardemann A, Weidemann H, Philipp M, Katz N, Tillmanns H, Hehrlein FW, et al. TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J 1999; 20: 584-92.